According to topline results released by the manufacturer, ocrelizumab reduced the risk of increased disability in primary progressive MS by 24% compared to placebo. In relapsing remitting MS, ocrelizumab reduced the number of relapses by 50% compared to interferon beta 1a (Rebif)
People with relapsing remitting MS should be considering starting disease modifying treatment as early as possible and be active partners in treatment choices according to newly revised guidelines published today by the ABN.
A study has reported that smokers who continued to smoke after being diagnosed with relapsing remitting MS reached the transition to secondary progressive MS more quickly than those who gave up smoking.
People with genes that cause them to have low levels of vitamin D are more likely to develop MS according to new research
The FDA has announced that it will update the information for Gilenya (fingolimod) after two possible cases of PML in people with MS taking this disease modifying drug in the USA.
The Scientific Advisory Committee on Nutrition (SACN), an independent body which advises the Government on diet, nutrition and health matters, have published their draft recommendations on vitamin D which are now out for public consultation until 23 September.
Triggers for palliative care, a report by Marie Curie, suggests that people with neurological conditions including MS are missing out on care that can make a real difference to quality of life. It shows that there is limited understanding from both health professionals and the public of what palliative care can offer, who can benefit and when the time is right time to access this holistic care.
Laboratory studies have shown two treatments currently used to treat skin conditions may have the potential to be developed into therapies to repair myelin in people with MS. However, this is very early research in animals and human cells, so the press coverage reporting the treatments as a 'cure', or 'reversing' or 'stopping' MS is somewhat premature.